![Pierre Thibault](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Pierre Thibault first degree
Entity | Entity type | Industry | |
---|---|---|---|
SpecificiT Pharma, Inc.
![]() SpecificiT Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SpecificiT Pharma, Inc. develops personalized cancer immunotherapies. The company is headquartered in Westmount, Canada.
4
| Holding Company | Miscellaneous Commercial Services | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Pierre Thibault via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
BioVex Group, Inc.
![]() BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Director/Board Member | |
University of Cambridge | College/University | Doctorate Degree | |
Concordia University-Irvine | College/University | Undergraduate Degree | |
Aegera Therapeutics, Inc.
![]() Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Biotechnology | Director/Board Member | |
GeneChem Management, Inc.
![]() GeneChem Management, Inc. Investment ManagersFinance GeneChem Management Inc (GeneChem) is an independent venture capital firm founded in 1997. The firm is headquartered in Montréal. | Investment Managers | Private Equity Investor | |
Réseau Capital
![]() Réseau Capital Miscellaneous Commercial ServicesCommercial Services Réseau Capital operates as a venture capital and private equity association. It promotes private equity industry in Quebec through training, information and promotion, networking, and representation. The company was founded by Jean-Pierre Chartrand in 1989 and is headquartered in Montréal, Canada. | Miscellaneous Commercial Services | Director/Board Member | |
AgeChem Financial, Inc.
![]() AgeChem Financial, Inc. Financial ConglomeratesFinance AgeChem Financial, Inc. engages in the provision of investment services, It seeks to invest in companies developing therapeutics targeting age-related diseases. The company was founded in 2006 and is headquartered in Montreal, Canada. | Financial Conglomerates | Director/Board Member | |
AmorChem Financial, Inc.
![]() AmorChem Financial, Inc. Financial ConglomeratesFinance AmorChem Financial, Inc. provides financial investment services. The company is headquartered in Westmount, Canada. | Financial Conglomerates | Founder | |
Centre For Commercialization of Cancer Immunotherapy
![]() Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada. | Founder | ||
Epitopea Ltd.
![]() Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Miscellaneous Commercial Services | Founder |
Statistics
International
Canada | 8 |
United States | 4 |
United Kingdom | 3 |
Sectoral
Health Technology | 4 |
Finance | 4 |
Commercial Services | 4 |
Consumer Services | 3 |
Operational
Director/Board Member | 8 |
Founder | 6 |
Private Equity Investor | 1 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Most connected contacts
Insiders | |
---|---|
Inès Holzbaur | 11 |
Claude Perreault | 2 |
Denis Roy | 2 |
Jean Delisle | 1 |
- Stock Market
- Insiders
- Pierre Thibault
- Company connections